Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightThese results suggest a potential therapeutic synergy between EGCG and 5-FU in managing liver injury and cancer treatment.
📌 3 Maddede Bu Makale
Abstract
This study aimed to assess the potential of epigallocatechin-3-gallate (EGCG) in mitigating 5-fluorouracil (5-FU)-induced hepatotoxicity using the AML12 cell line. In our study, we utilized the AML-12 cell line and divided it into four groups: control, 5-FU, EGCG, and EGCG+FU. The IC50 values were determined using the MTT assay. Expression levels of antioxidant system-associated genes, including Glutathione, catalase, and superoxide dismutase, were analyzed through qRT-PCR. Additionally, qRT-PCR analysis was employed to evaluate the expression of apoptosis-associated genes such as Caspase (Cas)-9, Apaf-1, Cas-3, Bax, and Bcl-2. Furthermore, the gene expressions of p53 and the smac/DIABLO were investigated. When EGCG was administered together with 5-FU GSH, SOD, and CAT mRNA expression levels increased. 5-FU administration statistically significantly elevated smac/DIABLO, Bax, Apaf-1, Bcl-2, and Cas-3 mRNA expression levels by stimulating apoptosis. When EGCG was administered together with 5-FU, Cas-9, Bax, Apaf-1, p53, Cas-3 and smac/DIABLO mRNA expressions elevated significantly, indicating the elimination of damaged structures through apoptosis. In conclusion, our findings indicate that EGCG confers hepatoprotective effects against 5-FU-induced damage through its antioxidant properties. Moreover, EGCG enhances the anticancer efficacy of 5-FU by promoting apoptosis, thereby facilitating the elimination of damaged cells. These results suggest a potential therapeutic synergy between EGCG and 5-FU in managing liver injury and cancer treatment.